Apollo Medical Holdings Inc (NASDAQ:AMEH) has received an average broker rating score of 2.00 (Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating.
Brokers have set a 1-year consensus price target of $27.50 for the company and are forecasting that the company will post $0.12 EPS for the current quarter, according to Zacks. Zacks has also given Apollo Medical an industry rank of 147 out of 255 based on the ratings given to its competitors.
Several research analysts recently commented on the company. Zacks Investment Research downgraded Apollo Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. ValuEngine upgraded Apollo Medical from a “hold” rating to a “buy” rating in a report on Tuesday, January 29th.
NASDAQ AMEH traded up $0.05 during mid-day trading on Wednesday, hitting $19.67. The stock had a trading volume of 271 shares, compared to its average volume of 13,966. Apollo Medical has a twelve month low of $13.01 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.20 and a quick ratio of 2.20.
Apollo Medical (NASDAQ:AMEH) last posted its quarterly earnings data on Wednesday, November 14th. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.15. The firm had revenue of $167.28 million during the quarter. On average, equities research analysts expect that Apollo Medical will post 0.49 earnings per share for the current fiscal year.
In other Apollo Medical news, insider Adrian Vazquez sold 221,597 shares of the company’s stock in a transaction on Wednesday, November 21st. The stock was sold at an average price of $17.55, for a total value of $3,889,027.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Warren Hosseinion sold 40,000 shares of the company’s stock in a transaction on Tuesday, November 20th. The shares were sold at an average price of $18.28, for a total value of $731,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 361,597 shares of company stock valued at $6,325,227. 20.50% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in shares of Apollo Medical by 63.4% during the 4th quarter. Bank of New York Mellon Corp now owns 59,862 shares of the company’s stock worth $1,188,000 after purchasing an additional 23,217 shares during the period. BlackRock Inc. grew its holdings in shares of Apollo Medical by 8.7% during the 4th quarter. BlackRock Inc. now owns 353,218 shares of the company’s stock worth $7,012,000 after purchasing an additional 28,411 shares during the period. Finally, Vanguard Group Inc grew its holdings in shares of Apollo Medical by 184.8% during the 3rd quarter. Vanguard Group Inc now owns 928,911 shares of the company’s stock worth $20,501,000 after purchasing an additional 602,710 shares during the period. Institutional investors own 6.70% of the company’s stock.
About Apollo Medical
Apollo Medical Holdings, Inc, an integrated health care delivery and management company, provides medical care services. The company offers care coordination services to principal constituents of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Featured Story: Why is Cost of Capital Important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.